Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $58.81 Million |
|---|---|
| Enterprise Value | $62.17 Million |
| Earnings per Share | $-0.04 |
| Beta | -0.35 |
| Outstanding Shares | 76,378,098 |
| P/E Ratio | -19.32 |
|---|---|
| PEG | -611.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -16.7 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.29 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to i...